The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: Role of endogenous TLR ligands

Journal of Pathology

Volumn 231, Issue 2, 2013, Pages 199-209

  Uaesoontrachoon, Kitipong ^a   Cha, Hee Jae ^a,b   Ampong, Beryl ^a   Sali, Arpana ^a   Vandermeulen, Jack ^a   Wei, Benjamin ^a   Creeden, Brittany ^a   Huynh, Tony ^a,c   Quinn, James ^a   Tatem, Kathleen ^a   Rayavarapu, Sree ^a,d   Hoffman, Eric P ^a,d   Nagaraju, Kanneboyina ^a,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Kosin University College of Medicine   (South Korea)

^c The Australian National University   (Australia)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

degeneration; dysferlin; inflammation; osteopontin; regeneration; single stranded RNA; Toll like receptor

Indexed keywords

DYSFERLIN; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL INFILTRATION; DISEASE COURSE; DOWN REGULATION; DYSFERLINOPATHY; GENE EXPRESSION; GENOTYPE; GRIP STRENGTH; MONONUCLEAR CELL; MOUSE; MUSCLE INJURY; MYELOID DIFFERENTIATION FACTOR 88 DEFICIENCY; MYOSITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; UPREGULATION;

DEGENERATION; DYSFERLIN; INFLAMMATION; OSTEOPONTIN; REGENERATION; SINGLE-STRANDED RNA; TOLL-LIKE RECEPTOR;

ANIMALS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC DEFICIENCY SYNDROMES; LIGANDS; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYELOID DIFFERENTIATION FACTOR 88; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTORS;

EID: 84883897292     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4207     Document Type: Article

References (58)

1. Liu J, Aoki M, Illa I, et al., Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genet 1998; 20: 31-36.
2. Bashir R, Britton S, Strachan T, et al., A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nature Genet 1998; 20: 37-42.
3. Anderson LV, Davison K, Moss JA, et al., Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999; 8: 855-861.
4. Illa I, Serrano-Munuera C, Gallardo E, et al., Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001; 49: 130-134.
5. De Luna N, Freixas A, Gallano P, et al., Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 2007; 17: 69-76.
6. Ho M, Gallardo E, McKenna-Yasek D, et al., A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002; 51: 129-133.
7. Nagaraju K, Rawat R, Veszelovszky E, et al., Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 2008; 172: 774-785.
8. Ampong BN, Imamura M, Matsumiya T, et al., Intracellular localization of dysferlin and its association with the dihydropyridine receptor. Acta Myol 2005; 24: 134-144.
9. Huang Y, Laval SH, van Remoortere A, et al., AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 2007; 21: 732-742.
10. Klinge L, Laval S, Keers S, et al., From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 2007; 21: 1768-1776.
11. Bansal D, Miyake K, Vogel SS, et al., Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423: 168-172.
12. Han R, Campbell KP,. Dysferlin and muscle membrane repair. Curr Opin Cell Biol 2007; 19: 409-416.
13. Han R., Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle 2011; 1: 10.
14. Angelini C, Grisold W, Nigro V,. Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis. Acta Myol 2011; 30: 185-187.
15. Amato AA, Brown RH Jr., Dysferlinopathies. Handb Clin Neurol 2011; 101: 111-118.
16. Vinit J, Samson M Jr, Gaultier JB, et al., Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 2010; 29: 103-106.
17. Nguyen K, Bassez G, Krahn M, et al., Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007; 64: 1176-1182.
18. Rawat R, Cohen TV, Ampong B, et al., Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010; 176: 2891-2900.
19. McNally EM, Ly CT, Rosenmann H, et al., Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000; 91: 305-312.
20. Gallardo E, Rojas-Garcia R, de Luna N, et al., Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001; 57: 2136-2138.
21. Klinge L, Aboumousa A, Eagle M, et al., New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010; 81: 946-953.
22. Denhardt DT, Guo X,. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482.
23. Denhardt DT, Noda M, O'Regan AW, et al., Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055-1061.
24. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al., Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119: 1583-1594.
25. Pegoraro E, Hoffman EP, Piva L, et al., SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76: 219-226.
26. Uaesoontrachoon K, Yoo HJ, Tudor EM, et al., Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008; 40: 2303-2314.
27. Shinohara ML, Lu L, Bu J, et al., Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nature Immunol 2006; 7: 498-506.
28. Shinohara ML, Jansson M, Hwang ES, et al., T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci U S A 2005; 102: 17101-17106.
29. Shinohara ML, Kim HJ, Kim JH, et al., Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci U S A 2008; 105: 7235-7239.
30. Zhang X, Kimura Y, Fang C, et al., Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007; 110: 228-236.
31. Pasare C, Medzhitov R,. Control of B-cell responses by Toll-like receptors. Nature 2005; 438: 364-368.
32. St Paul M, Barjesteh N, Paolucci S, et al., Toll-like receptor ligands induce the expression of interferon-gamma and interleukin-17 in chicken CD4+ T cells. BMC Res Notes 2012; 5: 616.
33. Lerario A, Cogiamanian F, Marchesi C, et al., Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord 2010; 11: 157.
34. Han R, Frett EM, Levy JR, et al., Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010; 120: 4366-4374.
35. Farini A, Sitzia C, Navarro C, et al., Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 2012; 318: 1160-1174.
36. Ho M, Post CM, Donahue LR, et al., Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004; 13: 1999-2010.
37. Spurney CF, Gordish-Dressman H, Guerron AD, et al., Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009; 39: 591-602.
38. Rayavarapu S, Van der Meulen JH, Gordish-Dressman H, et al., Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010; 5: e12981.
39. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
40. Porter JD, Khanna S, Kaminski HJ, et al., A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002; 11: 263-272.
41. Hoffman EP, Gordish-Dressman H, McLane VD, et al., Alterations in osteopontin modify muscle size in females in both humans and mice. Med Sci Sports Exerc 2013; 45: 1060-1068.
42. Tidball JG,. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005; 288: R345-R353.
43. Takeda K, Akira S,. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
44. Matzinger P., The danger model: a renewed sense of self. Science 2002; 296: 301-305.
45. Lennon NJ, Kho A, Bacskai BJ, et al., Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003; 278: 50466-50473.
46. Kono H, Rock KL,. How dying cells alert the immune system to danger. Nature Rev Immunol 2008; 8: 279-289.
47. Lai Y, Di Nardo A, Nakatsuji T, et al., Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nature Med 2009; 15: 1377-1382.
48. Chen YW, Nagaraju K, Bakay M, et al., Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005; 65: 826-834.
49. Cheung EV, Tidball JG,. Administration of the non-steroidal anti-inflammatory drug ibuprofen increases macrophage concentrations but reduces necrosis during modified muscle use. Inflamm Res 2003; 52: 170-176.
50. Hodgetts S, Radley H, Davies M, et al., Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice. Neuromuscul Disord 2006; 16: 591-602.
51. Nguyen HX, Tidball JG,. Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J Physiol 2003; 547: 125-132.
52. Pizza FX, Hernandez IJ, Tidball JG,. Nitric oxide synthase inhibition reduces muscle inflammation and necrosis in modified muscle use. J Leukoc Biol 1998; 64: 427-433.
53. Fuse K, Chan G, Liu Y, et al., Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 2005; 112: 2276-2285.
54. Alchi B, Nishi S, Kondo D, et al., Osteopontin expression in acute renal allograft rejection. Kidney Int 2005; 67: 886-896.
55. Choi JS, Cha JH, Park HJ, et al., Transient expression of osteopontin mRNA and protein in amoeboid microglia in developing rat brain. Exp Brain Res 2004; 154: 275-280.
56. Scatena M, Liaw L, Giachelli CM,. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309.
57. Haslett JN, Sanoudou D, Kho AT, et al., Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 2002; 99: 15000-15005.
58. Hirata A, Masuda S, Tamura T, et al., Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin. Am J Pathol 2003; 163: 203-215.